Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Monday, 2nd December at 8:00 am
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease
Hepion's Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives – Including Challenges of Remaining a Stand-Alone Company